CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Amgen Inc. v. Apotex Inc.

1:16-cv-00926

Overview

Case Number 1:16-cv-00926
Filing Date 2016-10-11
Status Terminated
Termination Date 2017-09-11
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Apotex Corp. Operating Company

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Apotex Inc. Operating Company

Represented By

3 Attorneys Listed

Kaveh V. Saba

Email: ksaba@meiplaw.com

Steven A. Maddox

Email: Steven.Maddox@procopio.com

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Plaintiff

Amgen Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 1 proceeding
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (1 found):
PTAB: 1
USPTO PTAB Trial 2015-10-26
IPR2016-00085

Complex Innovations, LLC v. Amgen Inc.

U.S. Continuation Sibling (7829595)
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9375405
Rapid dissolution formulation of a calcium receptor-active compound
Filed: 2010-11-09
Issued: 2016-06-28
Active (1.1 yrs remaining)
Expires: 2027-12-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

9

Dispositive

0

Granted

0

Denied

0

Pending / Review

4

Motions by Category

Procedural / Extension Motion 8 Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending
Minute Entry for proceedings held before Judge Gregory M. Sleet - Scheduling Conference held on 2/23/2017. Discussion regarding the schedule and issues outlined...
Entry #β€” • 2017-02-23
Procedural / Extension Motion Pending
SO ORDERED - re (24 in 1:16-cv-00854-GMS, 20 in 1:16-cv-00927-GMS, 22 in 1:16-cv-00900-GMS, 26 in 1:16-cv-00882-GMS, 19 in 1:16-cv-00853-GMS, 23 in 1:16-cv-0088...
Entry #β€” • 2017-01-09
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to serve Initial Disclosures Puruant to Fed. R. Civ. P. 26(a) and Pursuant to Paragrah 3 of Default Standard for Discovery to January...
Entry #21 • 2017-01-06 Document →
Procedural / Extension Motion Pending
SO ORDERED - re (15 in 1:16-cv-00928-GMS, 17 in 1:16-cv-00855-GMS, 16 in 1:16-cv-00899-GMS, 16 in 1:16-cv-00925-GMS, 13 in 1:16-cv-00853-GMS, 19 in 1:16-cv-0088...
Entry #β€” • 2016-12-12
Procedural / Extension Motion Pending
SO ORDERED - re 17 STIPULATION TO EXTEND TIME for plaintiff to move, answer, or otherwise respond to defendants' counterclaim to December 16, 2016 filed by Amge...
Entry #β€” • 2016-12-12
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for plaintiff to move, answer, or otherwise respond to defendants' counterclaim to December 16, 2016 - filed by Amgen Inc.. (Blumenfe...
Entry #17 • 2016-12-09 Document →

Docket Entries

(67 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Apotex Corp., Apotex Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-2010708.) - filed by Amgen Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(dmp, ) (Entered: 10/12/2016)

Entry #1 • 2016-10-11
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 10/12/2016)

Entry #2 • 2016-10-11
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/23/2016. Date of Expiration of Patent: 09/22/2026. Thirty Month Stay Deadline: N/A. (dmp, ) (Entered: 10/12/2016)

Entry #3 • 2016-10-11
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,375,405 B2;. (dmp, ) (Entered: 10/12/2016)

Entry #4 • 2016-10-11
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Amgen Inc.. (dmp, ) (Entered: 10/12/2016)

Entry #5 • 2016-10-11
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc